K-numberK253597
Device nameAplio beyond and Aplio me Software V2.0 Diagnostic Ultrasound System
ApplicantCanon Medical Systems Corporation
Product codeIYN
Device classClass II
Decision dateJan 20, 2026
DecisionSubstantially Equivalent
Regulation892.1550
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Aplio beyond and Aplio me Software V2.0 are mobile diagnostic ultrasound systems used to visualize structures and dynamic processes within the human body for diagnosis across multiple clinical applications including fetal, abdominal, cardiac, vascular, and musculoskeletal imaging. The systems provide various imaging modes including B-mode, M-mode, Doppler modes, elastography, and acoustic attenuation mapping, and are intended for use by physicians or trained healthcare professionals in hospital and clinical settings.

Technological characteristics

The subject devices employ the same fundamental scientific technology as the predicate but differ in several ways: they use bipolar pulse transmission instead of linear pulse trains, simultaneously receive up to 128 channel signals versus 256 in the predicate, do not support 2D array transducers, lack DVI video output support, and have different monitor sizes. Some Aplio beyond features include Precision+ Fine Processing and Breast Scan Guide, while the Aplio me has more limited sensor-dependent features than the predicate device.

Test standards cited

Testing was conducted in accordance with ANSI AAMI ES60601-1:2005/(R)2012, IEC 60601-1-2 (2020), IEC 60601-2-37 (2015), IEC 62304 (2015), IEC 62359 (2017), and ISO 10993-1 (2018). The devices were designed under Quality System Regulations (21 CFR 820) and ISO 13485 standards. FDA guidance documents on diagnostic ultrasound systems and device software were referenced.

Substantial equivalence argument

The Aplio beyond and Aplio me V2.0 are substantially equivalent to the Aplio i700 V8.5 predicate device because they share the same clinical intended use, imaging modes, and fundamental technological characteristics, with documented differences shown to not raise new safety or effectiveness questions. The software architecture was largely unchanged when migrated to the subject devices, and bench testing confirmed no device dependencies affect previously demonstrated software performance. Newly developed transducers employ the same fundamental scientific technology and are substantially equivalent to existing predicate transducers.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →